Clinical Trials
293 trialsREVALLO
University Hospital, Bordeaux
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Masonic Cancer Center, University of Minnesota
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
Fred Hutchinson Cancer Center
IDARA
University Hospital, Caen
Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant
M.D. Anderson Cancer Center
CPIT001
Hackensack Meridian Health
Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older
Hackensack Meridian Health
Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib
University of Chicago
RE-NEZ-SENS
University Hospital, Montpellier
AlloRelapseMM
Universitätsklinikum Hamburg-Eppendorf
TOMMY
Institut Cancerologie de l'Ouest
Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma
M.D. Anderson Cancer Center
Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma
University of California, San Diego
Tasquinimod for the Treatment of Relapsed or Refractory Myeloma
University of Pennsylvania
AMBROBiMM
Assistance Publique - Hôpitaux de Paris
Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma
Mayo Clinic
Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant
Mayo Clinic
ImmunoCARE: Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised Individuals
Scripps Translational Science Institute
PROACT
Washington University School of Medicine
ST-067 and Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma
University of Washington
Noninvasive Detection and Assessment of Therapy Response in Multiple Myeloma Using Whole-Body MRI
University of Texas Southwestern Medical Center
BCMA-targeted LCAR-BCDR Cells in Patients With Relapsed/Refractory Multiple Myeloma
Shanghai Changzheng Hospital
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
Roswell Park Cancer Institute
CART-38 in Adult AML and MM Patients
University of Pennsylvania
Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps
Thomas Jefferson University
Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma
Mayo Clinic
FRE
Hackensack Meridian Health
Corneal Findings in Patients Treated With Belantamab Mafodotin
Medical University of Vienna
A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives
Thomas Jefferson University
Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
University of Maryland, Baltimore
Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy
Roswell Park Cancer Institute
Blood Samples to Identify Biomarkers of Busulfan
Fred Hutchinson Cancer Center
A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma
Hackensack Meridian Health
DarPAL
Fondazione IRCCS Policlinico San Matteo di Pavia
EMBRACE
Medical College of Wisconsin
Acupuncture for Chemo-Induced Peripheral Neuropathy in Multiple Myeloma Patients
Wake Forest University Health Sciences
Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies
University of California, San Francisco
PaCE-MM
UNC Lineberger Comprehensive Cancer Center
T-cell Receptor α/β Depleted Donor Lymphocyte Infusion
Baptist Health South Florida
64Cu-LLP2A for Imaging Multiple Myeloma
Washington University School of Medicine
Cryocompression Therapy for Peripheral Neuropathy in Patients With Multiple Myeloma
Wake Forest University Health Sciences
Effect of Sleep Quality on Hematopoietic Cell Transplant Patient Outcomes
Medical College of Wisconsin
Providing Cancer Care Closer to Home for Patients With Multiple Myeloma
Washington University School of Medicine
Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma
Columbia University
Precision Medicine for Patients With Identified Actionable Mutations
Wake Forest University Health Sciences
Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure
Emory University
Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma
Ohio State University Comprehensive Cancer Center
Heart Rate Variability, Vagus Nerve and Cancer
Centre Hospitalier Henri Duffaut - Avignon
The Risk Stratification in Patients With Multiple Myeloma Based on Fluorescence Flow Cytometry Quantitative Determination of the Circulating Plasma Cells in the Peripheral Blood
St. Petersburg State Pavlov Medical University